Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021358 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
A Phase 1 study of Lymphoma and Chronic Lymphocytic Leukemia, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01021358: Completed Phase 1 study of Lymphoma and Chronic Lymphocytic Leukemia, sponsored by Abbott.
NCT01021358 is a Phase 1 study of Lymphoma and Chronic Lymphocytic Leukemia that has completed, run by Abbott. The registered enrollment target is 12 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01021358, a Phase 1 study of Lymphoma and Chronic Lymphocytic Leukemia, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
Conditions Studied
Interventions
- DRUG Ketoconazole
- DRUG ABT-263
Study Locations (1)
Texas
- Site Reference ID/Investigator# 25068 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-01 |
| Phase | Phase 1 |
What the finished NCT01021358 record still lists
NCT01021358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Ketoconazole is the first listed.
NCT01021358 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01021358 about?
NCT01021358 is a clinical study titled "A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).". This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
What is the current status of trial NCT01021358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-01.
What conditions does trial NCT01021358 study?
This clinical trial studies the following conditions: Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors.
What interventions are being tested in trial NCT01021358?
The interventions under investigation include: Ketoconazole (DRUG), ABT-263 (DRUG).
Who is sponsoring clinical trial NCT01021358?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01021358 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01021358's enrollment target sits among peer trials
12 269th of 299 higher than 28 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia